PAOG Sees Broader Cannabis Pharma Treatment Opportunity

by Newsfeed


SANDUSKY, Ohio, Sept. 24, 2020 /PRNewswire/ — PAO Group, Inc. (USOTC: PAOG) today announced the company will expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).

On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).  RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” 

In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that…



Read Full Article Here